Transcriptomics reveals new regulatory mechanisms involved in benralizumab response

Estravís Sastre, Miguel; Pérez Pazos, Jacqueline; Moreno‐Jimenez, Emma; Triviño, Juan Carlos; García Sánchez, María Asunción; Gómez‐García, Manuel; Morgado, Natalia; Ramos González, Jacinto; Gil Melcón, María; Martín García, Cristina; Muñoz Bellido, Francisco Javier; Sanz Lozano, Catalina Sofía; Isidoro García, María; Dávila González, Ignacio Jesús

doi:10.1111/all.15869

Título

Transcriptomics reveals new regulatory mechanisms involved in benralizumab response

Autor(es)

Palabras clave

Benralizumab

Transcriptomics

Asthma biomarkers

CRSwNP

N-ERD

Exacerbated respiratory disease

Clasificación UNESCO

3207.01 Alergias

2409 Genética

Fecha de publicación

2023-11

Editor

Wiley

Citación

Estravís M, Pérez-Pazos J, Moreno-Jimenez E, Triviño JC, García-Sánchez A, Gómez-García M, Morgado N, Ramos-González J, Gil-Melcón M, Martín-García C, Muñoz-Bellido F, Sanz C, Isidoro-García M, Dávila I. Transcriptomics reveals new regulatory mechanisms involved in benralizumab response. Allergy. 2023 Nov;78(11):3023-3026. doi: 10.1111/all.15869. Epub 2023 Aug 28. PMID: 37641395.

Resumen

[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge. In this prospective observational study, we analyzed transcriptomic changes in peripheral whole blood samples from 15 severe asthmatic patients treated with benralizumab for 6 months. The study included patients with two frequent comorbidities: nasal polyposis (CRSwNP) and NSAID-exacerbated respiratory disease (N-ERD)

URI

https://hdl.handle.net/10366/158780

ISSN

0105-4538

DOI

10.1111/all.15869

Versión del editor

https://doi.org/10.1111/all.15869

Aparece en las colecciones